The Global Schizophrenia Drugs Market size is expected to exhibit a strong 2.5% CAGR over the forecast period from 2019 to 2025, according to the latest research report from Market Research Future (MRFR). The global Schizophrenia Drugs Market is expected to exhibit stable growth over the forecast period due to the growing awareness about the disease and the growing development of effective therapies against the disease. The MRFR report presents a comprehensive report of the global Schizophrenia Drugs Market including a detailed historical analysis of the market’s growth trajectory, an analysis of the major drivers and restraints affecting the market, and an assessment of the leading players operating in the market.
Competitive profiles are provided for every major player in the global Schizophrenia Drugs Market to provide a clear picture of where the major market players stand. Thus, a comprehensive overview of the global Schizophrenia Drugs Market is provided in the report. The global Schizophrenia Drugs Market was valued at USD 7.2 billion in 2018.
Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/1625
The Schizophrenia Drugs Market is mainly driven by the growing awareness about schizophrenia. Schizophrenia is a mental condition characterized by a breakdown in the relation between thought, emotion, and behavior. Its causes can be varied, but usually the condition is severe and disabling to the individual affected by it. It is also a persistent condition and can affect the individual for years on end.
The rising number of cases of schizophrenia is a major driver for the schizophrenia treatment market, as the increasing number of cases of the disease has led to growing awareness about the disease. According to the Schizophrenia and Related Disorders Alliance of America, around 1.1% of the world’s population is schizophrenic. According to the National Institute of Mental Health, schizophrenia is one of the top 15 causes of disability worldwide. This is a major driver for the global Schizophrenia Drugs Market.
Increasing research and development into schizophrenia is likely to be a major driver for the global Schizophrenia Drugs Market. On the other hand, stringent regulations affecting new product approvals and the rising number of generic drugs being developed to treat schizophrenia are likely to be key restraints against the global Schizophrenia Drugs Market.
Schizophrenia Drugs Market Competitive Leaderboard:
Leading players in the global Schizophrenia Drugs Market include Sumitomo Dainippon Pharma, Alkermes, Eli Lilly and Company, AstraZeneca, Otsuka Pharmaceuticals, Bristol-Myers Squibb and Company, and Johnson & Johnson. Major players in the global Schizophrenia Drugs Market are focusing on product development as a highly promising tactic in the global Schizophrenia Drugs Market.
Schizophrenia Drugs Market Segmentation:
The global Schizophrenia Drugs Market is segmented on the basis of type, treatment, route of administration, and region.
By type, the global Schizophrenia Drugs Market is segmented into paranoid schizophrenia, hebephrenic schizophrenia, catatonic schizophrenia, and undifferentiated schizophrenia.
By treatment, the global Schizophrenia Drugs Market is segmented into second-generation antipsychotics and third-generation antipsychotics drugs. The second-generation antipsychotics segment holds the dominant share in the global Schizophrenia Drugs Market and is segmented into Risperdal, Invega, Zyprexa, Geodon, Seroquel, Latuda, and others.
By route of administration, the global Schizophrenia Drugs Market is segmented into oral and injectables.
Schizophrenia Drugs Market Regional Analysis:
Geographically, the global Schizophrenia Drugs Market is segmented into the Americas, Europe, Asia Pacific, and the Middle East and Africa. The Americas is the major regional segment of the global Schizophrenia Drugs Market and is likely to retain a dominant share in the global market over the forecast period. Strong presence of research channels and product development channels in the region is the major driver for the Americas market for schizophrenia treatment. The growing awareness about schizophrenia and other associated disorders in the Americas is also a major driver for the market.
Europe is expected to be the second largest regional market for schizophrenia treatments, due to the growing prevalence of schizophrenia and the increasing number of geriatrics in the region.
Asia Pacific is also expected to be a major regional market for schizophrenia due to the growing awareness about the disease in the region. The growing prevalence of psychotic disorders in Asia Pacific is likely to be a major driver for the global Schizophrenia Drugs Market.
Browse Complete Research Report with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/schizophrenia-market-1625
NOTE: Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Media Contact
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar
City: Pune
State: Maharashtra
Country: India
Website: https://www.marketresearchfuture.com/reports/schizophrenia-market-1625